Skip to the main content

Acta Dermatovenerologica Croatica, Vol. 29 No. 1, 2021.

Case report

Vitiligo-like Depigmentation in a Patient Undergoing Treatment with Nivolumab for Advanced Renal-cell Carcinoma

Inigo Navarro-Fernandez ; Department of Dermatology, University Hospital Marqués de Valdecilla, Santander, Spain
Carmen Gonzalez- Vela ; Department of Pathology, University Hospital Marqués de Valdecilla, Santander, Spain
Cristina Gomez-Fernandez ; Department of Dermatology, University Hospital Marqués de Valdecilla, Santander, Spain
Carlos Duran- Vian ; Department of Dermatology, University Hospital Marqués de Valdecilla, Santander, Spain
Leandra Reguero ; Department of Dermatology, University Hospital Marqués de Valdecilla, Santander, Spain
Marcos Gonzalez- Lopez ; Department of Dermatology, University Hospital Marqués de Valdecilla, Santander, Spain

Full text: english pdf 110 Kb

page 54-55

downloads: 170

cite

Abstract

Nivolumab is a fully human monoclonal antibody
that targets the programmed cell death 1 (PD-1) immune
checkpoint. It has been approved for its use in
several types of advanced solid tumors, including melanoma,
lung cancer, and renal cell carcinoma (RCC).
The inhibition of PD-1 leads to an enhanced adaptive
immune response against tumor cells through the activation
of T-cells.

Keywords

Hrčak ID:

274447

URI

https://hrcak.srce.hr/274447

Publication date:

17.3.2021.

Visits: 439 *